Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx, Pfizer Submit NDAs For Fast-Track Kidney Cancer Agents

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bayer and Onyx expect to launch their renal cell carcinoma therapy BAY 43-9006 (sorafenib) in the first half of 2006

You may also be interested in...



Bayer/Onyx Nexavar trial update

Bayer/Onyx' interim analysis of a pivotal renal cell carcinoma trial of Nexavar (sorafenib), conducted after placebo-treated patients crossed over to Nexavar, finds that the oral multi-kinase inhibitor "did not reach statistical significance (p<0.0005)," the firms say Nov. 3. Nevertheless, "these early results suggest a favorable survival trend." Based on the cross-over analysis, "there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo (p=0.018; hazard ratio=0.72)." The analysis was based on 220 survival events (patient deaths), while the final analysis is planned "when 540 events have occurred." The Nexavar NDA, submitted July 11, is based on 24-week data from the trial, in which a highly statistically significant progression-free survival benefit was seen (1Pharmaceutical Approvals Monthly August 2005, p. 14)...

Bayer/Onyx BAY 43-9006 Interim Analysis To Support Accelerated NDA Filing

Onyx expects its kidney cancer therapy BAY 43-9006 to receive accelerated approval by 2006 based on initial Phase III data showing statistically significantly longer progression-free survival versus placebo

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel